Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462831 | 0.86 | CHRNB2 (0.56) | SMN1; SMN2POLBCHRNA4CHRNB2CHRNB4 | |
| SCHEMBL20346316 | 0.75 | SMN1; SMN2 (0.97) | SMN1; SMN2POLBALDH1A1NPC1RAB9A | |
| SCHEMBL24815673 | 0.74 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1NPC1RAB9A | |
| SCHEMBL12425968 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBALDH1A1NPC1RAB9A | |
| SCHEMBL29986910 | 0.74 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1NPC1RAB9A | |
| SCHEMBL1462738 | 0.73 | CHRNA4 (0.62) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28762510 | 0.72 | BPTF (0.52) | POLBCHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1914984 | 0.72 | BPTF (0.52) | POLBCHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14704709 | 0.72 | BPTF (0.52) | POLBCHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12385780 | 0.71 | SMN1; SMN2 (0.66) | SMN1; SMN2POLBKMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | claimed |
| EP-2257549-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | Targacept Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2257549-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | Targacept Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA7, CHRNA2, CHRNA5 | SMN1; SMN2 330/4885POLB 3821/4885CHRNA4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.